Evidence map›Paper›PMID 38515057›Full record

ArticleBMC cancer2024

Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.

Huiyang Ren, Zhen Wang, Lei Zhang, Guolian Zhu, Feng Li, Bo Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Huiyang RenDepartment of Breast Surgery, the First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang City, Liaoning, 110001, China. renhuiyang2015@163.com.
Zhen WangDepartment of Breast Surgery, the First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang City, Liaoning, 110001, China. wangzhen_1997@126.com.
Lei ZhangDepartment of Breast Surgery, the First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang City, Liaoning, 110001, China. zhl656144@163.com.
Guolian ZhuDepartment of Breast Surgery, the Fifth People's Hospital of Shenyang, 188 Xingshun Street, Tiexi District, Shenyang City, Liaoning, 110023, China. 490052343@qq.com.
Feng LiDepartment of Cell Biology, Key Laboratory of Cell Biology of National Health Commission of the PRC, Key Laboratory of Medical Cell Biology of Ministry of Education of the PRC, China Medical University, No.77, Puhe Road, Shenyang, Liaoning, 110122, China. lifeng@cmu.edu.cn.
Bo ChenDepartment of Breast Surgery, the First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang City, Liaoning, 110001, China. bochen@cmu.edu.cn.
China Medical University · CNFirst Hospital of China Medical University · CNNational Health and Family Planning Commission · CNShenyang Fifth People Hospital · CN

Funding

"Double First-Class": Clinical Medicine Symbolic Achievement Support Program of the Office of Development and Planning, China Medical University 3110200339Mcajor Scientific and Technological Innovative Research and Development Project of Shenyang 19-112-4-094Program of the Distinguished Professor of Liaoning Province, Breast Cancer 28019Subject Development Project of China Medical University 3110117053Tackling Key Problems and Serving Local Projects of Liaoning Province ZF20190006
6 · The paper itself

Abstract

backgroundCell adhesion molecule 3 (CADM3), a transmembrane glycoprotein on cell membranes, plays a role in the way of ligand and receptor interaction. However, there are few studies on CADM3 in tumors, and how it works in breast cancer (BC) remains unclear.

methodsThe Cancer Genome Atlas (TCGA) database and clinical samples were used to analyze CADM3 expression and its correlation with clinicopathological factors and prognosis. Its correlation with immune infiltration was analyzed by TCGA. The effects of CADM3 on proliferation and migration were investigated by cell clonal formation, CCK-8, cell scratch and transwell assay. Protein interaction network was prepared and the function prediction of related genes was conducted. The correlation between CADM3 and MAPK pathway was further explored by western blot experiment.

resultsThe expression of CADM3 in BC tissues were significantly lower than that in adjacent normal tissues. High level of CADM3 was related to better prognosis of BC patients. CADM3 was an independent prognostic factor for BC. Expression of CADM3 was significantly associated with the status of ER and PR, age and PAM50 subtypes. CADM3 positively related to many immune infiltrating cells. Overexpression of CADM3 can notably reduce cell proliferation and migration. CADM3 was related to MAPK pathway and the phosphorylation of ERK1/2 and JNK1 was inhibited in BC cells with high CADM3.

conclusionsOur research reveals the clinical significance of CADM3 in BC and indicates the critical roles of CADM3 in immune infiltration and MAPK pathway.

Indexed as

Breast NeoplasmsCell Adhesion MoleculesCell Line, TumorClinical RelevanceFemaleGene Expression Regulation, NeoplasticHumansImmunoglobulinsPrognosisCADM3 protein, humanCell Adhesion MoleculesImmunoglobulinsBreast cancerCADM3Clinic pathological featuresMAPK pathwayMigrationProliferation

Identifiers

PMID38515057
PMCPMC10958964
OpenAlexW4393037583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.